Jiang J, van Rhee A M, Chang L, Patchornik A, Ji X D, Evans P, Melman N, Jacobson K A
Molecular Recognition Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
J Med Chem. 1997 Aug 1;40(16):2596-608. doi: 10.1021/jm970091j.
4-(Phenylethynyl)-6-phenyl-1,4-dihydropyridine derivatives are selective antagonists at human A3 adenosine receptors, with Ki values in a radioligand binding assay vs [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)-5'-(N-methylcarbamoyl)adenosine) in the submicromolar range. In this study, structure-activity relationships at various positions of the dihydropyridine ring (the 3- and 5-acyl substituents, the 4-aryl substituent, and 1-methyl group) were probed synthetically. Using the combined protection of the 1-ethoxymethyl and the 5-[2-(trimethylsilyl)ethyl] ester groups, a free carboxylic acid was formed at the 5-position allowing various substitutions. Selectivity of the new analogues for cloned human A3 adenosine receptors was determined vs radioligand binding at rat brain A1 and A2A receptors. Structure-activity analysis at adenosine receptors indicated that pyridyl, furyl, benzofuryl, and thienyl groups at the 4-position resulted in, at most, only moderate selectivity for A3 adenosine receptors. Ring substitution (e.g., 4-nitro) of the 4-phenylethylnyl group did not provide enhanced selectivity, as it did for the 4-styryl-substituted dihydropyridines. At the 3-position of the dihydropyridine ring, esters were much more selective for A3 receptors than closely related thioester, amide, and ketone derivatives. A cyclic 3-keto derivative was 5-fold more potent at A3 receptors than a related open-ring analogue. At the 5-position, a homologous series of phenylalkyl esters and a series of substituted benzyl esters were prepared and tested. (Trifluoromethyl)-, nitro-, and other benzyl esters substituted with electron-withdrawing groups were specific for A3 receptors with nanomolar Ki values and selectivity as high as 37000-fold. A functionalized congener bearing an [(aminoethyl)amino]carbonyl group was also prepared as an intermediate in the synthesis of biologically active conjugates.
4-(苯乙炔基)-6-苯基-1,4-二氢吡啶衍生物是人类A3腺苷受体的选择性拮抗剂,在放射性配体结合试验中,其对[125I]AB-MECA(N6-(4-氨基-3-碘苄基)-5'-(N-甲基氨基甲酰基)腺苷)的Ki值处于亚微摩尔范围。在本研究中,通过合成方法探究了二氢吡啶环各个位置(3-和5-酰基取代基、4-芳基取代基和1-甲基)的构效关系。利用1-乙氧基甲基和5-[2-(三甲基甲硅烷基)乙基]酯基的联合保护,在5-位形成游离羧酸,从而允许进行各种取代。通过与大鼠脑A1和A2A受体的放射性配体结合试验,测定了新类似物对克隆的人类A3腺苷受体的选择性。腺苷受体的构效分析表明,4-位的吡啶基、呋喃基、苯并呋喃基和噻吩基最多仅对A3腺苷受体具有中等选择性。4-苯乙炔基的环取代(如4-硝基)并未像4-苯乙烯基取代的二氢吡啶那样提供增强的选择性。在二氢吡啶环的3-位,酯对A3受体的选择性远高于密切相关的硫酯、酰胺和酮衍生物。一种环状3-酮衍生物在A3受体上的活性比相关的开环类似物高5倍。在5-位,制备并测试了一系列苯基烷基酯和一系列取代苄基酯。(三氟甲基)-、硝基-和其他带有吸电子基团取代的苄基酯对A3受体具有特异性,Ki值为纳摩尔级,选择性高达37000倍。还制备了一种带有[(氨基乙基)氨基]羰基的功能化同系物,作为生物活性缀合物合成的中间体。